Difficulty: Medium
Average Score: 64%
Practice
Propylthiouracil can produce:
Correct answer
B
Rationale
Propylthiouracil is a medication used in the treatment of hyperthyroidism by inhibiting the conversion of the thyroid hormone thyroxine (T4) to triiodothyronine (T3) in the peripheral tissues. This is the correct answer (B) because propylthiouracil acts by blocking the enzyme responsible for this conversion, thus reducing the levels of the more active T3 hormone in the body.
Option A, "Inhibit iodine uptake," is incorrect because propylthiouracil does not directly inhibit iodine uptake by the thyroid gland. Its mechanism of action lies in interfering with hormone conversion, not iodine uptake.
Option C, "Decrease size of goiter," is incorrect because propylthiouracil's primary effect is on thyroid hormone levels, not on reducing the size of the goiter itself. Treatment with propylthiouracil may eventually lead to a decrease in goiter size indirectly by normalizing thyroid hormone levels.
Option D, "Decrease exophthalmos," is incorrect because propylthiouracil does not directly address the eye symptoms associated with hyperthyroidism, such as exophthalmos. Exophthalmos is more related to the autoimmune process affecting the eye muscles in Grave's disease, which is not the primary target of propylthiouracil.
Understanding the specific pharmacological actions of propylthiouracil is crucial for healthcare professionals managing patients with hyperthyroidism. By grasping how this medication works, they can make informed decisions about the appropriate treatment for each individual, ensuring optimal outcomes and patient safety.
Option A, "Inhibit iodine uptake," is incorrect because propylthiouracil does not directly inhibit iodine uptake by the thyroid gland. Its mechanism of action lies in interfering with hormone conversion, not iodine uptake.
Option C, "Decrease size of goiter," is incorrect because propylthiouracil's primary effect is on thyroid hormone levels, not on reducing the size of the goiter itself. Treatment with propylthiouracil may eventually lead to a decrease in goiter size indirectly by normalizing thyroid hormone levels.
Option D, "Decrease exophthalmos," is incorrect because propylthiouracil does not directly address the eye symptoms associated with hyperthyroidism, such as exophthalmos. Exophthalmos is more related to the autoimmune process affecting the eye muscles in Grave's disease, which is not the primary target of propylthiouracil.
Understanding the specific pharmacological actions of propylthiouracil is crucial for healthcare professionals managing patients with hyperthyroidism. By grasping how this medication works, they can make informed decisions about the appropriate treatment for each individual, ensuring optimal outcomes and patient safety.